Breast Cancer News
In this section, access cutting-edge breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
A recent study suggests that while women are living longer after treatment for breast cancer, they may be at greater risk of developing certain health conditions as they age.
The final analysis of survival data from the Comparison of Faslodex in Recurrent or Metastatic Breast Cancer (CONFIRM) trial is encouraging. Researchers confirmed what was seen as a trend in their initial secondary analysis: postmenopausal women with metastatic, hormone-positive breast cancer lived longer when given twice the past standard amount of fulvestrant (Faslodex).
More and more women are choosing breast reconstruction following mastectomy, partially due to the considerable rise in use of bilateral mastectomy.
Although concerned about how breast cancer treatment might affect their future ability to have children, few young women take steps to preserve fertility before treatment.
Compared with standard radiation therapy, brachytherapy — a method of confining radiation to the tumor site — may similarly reduce the risk of future mastectomy among some older women with early-stage disease.
Many young women diagnosed with breast cancer find that their relationship with their mother improves after diagnosis. Daughters were more likely to seek out support from their mothers after diagnosis than they were in the previous year.
Women with stage III breast cancer or who are diagnosed with triple-negative or HER2-positive disease may live longer when starting chemotherapy no more than 30 days after surgery, research shows.
According to a study recently published in the Journal of Clinical Oncology, practicing Hatha yoga for as few as 3 months may lessen fatigue and inflammation in people treated for breast cancer.
Exercising often after breast cancer treatment ends may help women improve their quality of life over time, say researchers from the University of Illinois at Urbana-Champaign.
Researchers found the same amount of tumor cells present at surgery among two groups of women receiving therapy for HER2-positive breast cancer. The first group was treated before surgery with trastuzumab (Herceptin) plus paclitaxel (Taxol), followed by anthracycline chemotherapy. The second received the same treatment, but with more trastuzumab given at the same time as the anthracycline. This finding lends support to past studies showing trastuzumab is not needed during anthracycline (e.g., doxorubicin or epirubicin) treatment to shrink or get rid of the cancer before surgery.